Meeting
2018 ASCO Annual Meeting
Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.
Authors
James Lorens
BerGenBio ASA, Bergen, Norway
James Lorens , Carlos Eduardo Arce-Lara , Edurne Arriola , Paal Brunsvig , Enric Carcereny Costa , Manuel Domine , Konstantin H. Dragnev , Enriqueta Felip , Rosario Garcia Campelo , Matthew Krebs , Santiago Ponce Aix , James F. Spicer , Jose Manuel Trigo Perez , Nuria Vinolas , Robert J Holt , Anthony Brown , Michael Jon Chisamore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03184571
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3078)
DOI
10.1200/JCO.2018.36.15_suppl.3078
Abstract #
3078
Poster Bd #
292
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2016 ASCO Annual Meeting
A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
First Author: Benjamin Philip Levy
Poster
2022 ASCO Annual Meeting
PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.
First Author: Giuseppe Lo Russo
Poster
2022 ASCO Annual Meeting
Platinum-free chemotherapy in the new era of immunotherapy: A phase II study of camrelizumab combined with apatinib and albumin paclitaxel in advanced non-squamous NSCLC (CAPAP-lung).
First Author: Lin Wu